Glaukos Corporation · NYSE:GKOS

Glaukos — Investor Presentation (August 2023)

31 slides from Glaukos's investor presentation, August 2023

  1. Slide 1: Investor Presentation August 2023

    Slide 1: Investor Presentation August 2023

    Investor Presentation August 2023

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current e

  3. Slide 3: We'll Go First

    Slide 3: We'll Go First

    WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases. © 2023 Glaukos Corporation 3

  4. Slide 4: Our Core Strategy

    Slide 4: Our Core Strategy

    Our Core Strategy Designed to drive long-term growth and value creation 1. BIG IDEAS 2. SIGNIFICANT CLINICAL NEED 3. SPECIALIZED R&D TEAMS 4. EXPERIENCED SALES ORGANIZATION 5. PROVEN MARKET BUILDER 6. EFFICIENT GLOBAL OPERATIONS © 2023 Glaukos Corporation 4

  5. Slide 5: Our Big Ideas

    Slide 5: Our Big Ideas

    OUR BIG IDEAS Develop novel dropless therapies to 5 distinct platforms disrupt legacy generating disruptive, dropless innovations topical eye drop across 3 franchises therapies plagued by rampant patient non-adherence $400M invested investedininR&D R&Dsince since2018 2018 14 Disclosed pipeline progr

  6. Slide 6: Glaucoma

    Slide 6: Glaucoma

    GLAUCOMA Topical medications are the dominant treatment plan for the The conventional glaucoma patient journey is being re-examined roughly 18M US eyes1 affected by Aqueous glaucoma and ocular hypertension SLT + shunt 1 topical 2 topical 3+ topical Filtering Research2 shows that med meds topical med

  7. Slide 7: Interventional Glaucoma

    Slide 7: Interventional Glaucoma

    INTERVENTIONAL GLAUCOMA Interventional Glaucoma represents Proactive glaucoma Glaukos’ founding promise to radically alter management via predictive the conventional treatment algorithm diagnostics, active patient monitoring and procedural intervention earlier in the MIGS therapies safely and effect

  8. Slide 8: Interventional Glaucoma

    Slide 8: Interventional Glaucoma

    INTERVENTIONAL GLAUCOMA With the only comprehensive glaucoma portfolio Creates 2 pathways for fluid Creates 3 pathways for up to 240° of fluid outflow; wider flange enhances outflow coverage; failed prior medical and Trabecular Bypass ease of use and visibility surgical therapy Sustained-Release Sta

  9. Slide 9: First-ever micro-invasive implantable device for standalone glaucoma treatment

    Slide 9: First-ever micro-invasive implantable device for standalone glaucoma treatment

    12-MONTH CLINICAL TRIAL RESULTS5 First-ever micro-invasive implantable device for standalone glaucoma treatment 76 % of subjects achieved 20% or greater reduction in • Three micro-stents designed to provide up to 240° of sustained, 24/7 outflow mean IOP on same or lower medication burden • Pivotal t

  10. Slide 10: The next major addition to the Interventional Glaucoma arsenal

    Slide 10: The next major addition to the Interventional Glaucoma arsenal

    The next major addition to the Designed to address Interventional Glaucoma arsenal ubiquitous patient non- adherence to and • Designed to provide long-duration intracameral pharmaceutical; secure and chronic side effects anchored design; facile implantation and associated with topical exchange • Mem

  11. Slide 11: Phase 3 data achieves primary efficacy endpoints

    Slide 11: Phase 3 data achieves primary efficacy endpoints

    Phase 3 data achieves primary efficacy endpoints In 2 pivotal trials, iDose IOP REDUCTIONS FROM BASELINE OBSERVED DURING FIRST 3 MONTHS1 TR fast- and slow- • 1,150 subjects randomized release doses achieved 8.5 8.4 across both Phase 3 trials IOP Reductions from Baseline (mmHg) • Mean baseline IOP of

  12. Slide 12: First-of-its-kind real-world effectiveness data for iDose TR

    Slide 12: First-of-its-kind real-world effectiveness data for iDose TR

    iDose TR demonstrated statistically significant superior IOP-lowering vs pre-study PGAs in sub-group analysis of First-of-its-kind real- combined Phase 3 trials world effectiveness IOP VALUES ON PRE-STUDY PGAs, AFTER PGA • 125 subjects across both Phase 3 data further validates WASHOUT, AND AFTER 3

  13. Slide 13: Phase 3 and Phase 2b duration data for iDose TR

    Slide 13: Phase 3 and Phase 2b duration data for iDose TR

    Phase 3 and Phase 2b duration data for iDose TR iDose TR: AT 12 MONTHS AT 24 MONTHS AT 36 MONTHS 93% The data PH 3 Percentage of slow- that matters iDose TR subjects well- to doctors, controlled on the same patients and 92% 72% 69% fewer IOP-lowering PH 2B medications payors of slow-release iDose TR

  14. Slide 14: Phase 2b: iDose TR arm controls IOP in more patients vs eyedrop arm

    Slide 14: Phase 2b: iDose TR arm controls IOP in more patients vs eyedrop arm

    % PATIENTS WELL CONTROLLED ON THE SAME OR FEWER TOPICAL IOP-LOWERING Phase 2b: iDose MEDS IN PHASE 2B TRIAL AT 3 YEARS TR arm controls 69% vs IOP in more patients vs 1 eyedrop arm at 45% 2,190 3 years 2,190 eye drops administered per eye per 3-yr protocol in Phase 2b control arm vs one administratio

  15. Slide 15: Phase 3 and Phase 2b safety data for iDose TR

    Slide 15: Phase 3 and Phase 2b safety data for iDose TR

    Phase 3 and Phase 2b safety data for iDose TR iDose TR: iDose TR The data Topical PGAs Ph 3 Trials Ph 2b Trial that matters 1 Year 3 Years to doctors, No adverse events of periorbital Up to 70% incidence patients and fat atrophy payors Very low or no conjunctival 30%-50% incidence hyperemia No adver

  16. Slide 16: Exchange trial: corneal endothelial cell density

    Slide 16: Exchange trial: corneal endothelial cell density

    Exchange trial conducted No clinically meaningful changes in corneal on re-administration of endothelial cell counts over 5+ years iDose TR 3000 • Prospective, multi-center trial to 2500 evaluate safety of exchange procedure Corneal Endothelial Cell Density Exchange study’s positive 2000 • Study enr

  17. Slide 17: iDose TR has potential to address rampant patient non-compliance

    Slide 17: iDose TR has potential to address rampant patient non-compliance

    Clinical trial efficacy data iDose TR has In Phase 3 trials, 93% of subjects were well-controlled and 81% of subjects were completely free of IOP-lowering iDose TRmedications is not approved byatthe 12FDAmonths; Phase 2b trial revealed 69% of subjects still well-controlled at 36 months potential to

  18. Slide 18: Interventional Glaucoma Portfolio

    Slide 18: Interventional Glaucoma Portfolio

    INTERVENTIONAL GLAUCOMA PORTFOLIO PRODUCT PATIENT STATUS Addressing the full range of iStent / iStent inject / Approved CATARACT COMBO- Mild-to-Moderate Glaucoma with Cataract iStent inject W (2012 / 2018 / 2020) glaucoma progression Glaucoma iStent infinite (failed on prior medical and surgical the

  19. Slide 19: iLink Platform

    Slide 19: iLink Platform

    iLINK PLATFORM Bio-activated corneal cross-linking therapy for keratoconus, a sight- First and only FDA-approved bio-activated pharmaceutical threatening, life-altering disease therapy shown to slow or halt progression of keratoconus. with typical onset in adolescence Without effective treatment, 1

  20. Slide 20: Epioxa (Epi-on)

    Slide 20: Epioxa (Epi-on)

    Demonstrated ability to halt or reduce keratoconus progression (n=279 eyes) Epioxa Achieved primary efficacy outcome by demonstrating In treatment arm, Kmax improved After initial 6-month follow-up, Epi-On is designed to reduce treatment time (Epi-on) Kmax treatment effect of -1.0D 0.2D 98% and comp

  21. Slide 21: iLution Platform

    Slide 21: iLution Platform

    iLUTION PLATFORM Transdermal dropless therapy with the potential to treat a variety of chronic eye diseases and disorders Eyelid delivery offers potential for easier administration, faster onset of action, fewer side effects and other benefits vs prescription eye drops used to treat dry eye disease

  22. Slide 22: GLK-301 Phase 2a first-time-in-human results

    Slide 22: GLK-301 Phase 2a first-time-in-human results

    iLution Dry Eye (GLK- GLK-301 Phase 2a first-time-in-human results show 301) Phase 2a Trial: 218 dry eye patients promise to progress to Phase 2b trial TEAR BREAK-UP TIME, PERCENT were studied for 28 CHANGE FROM BASELINE AT DAY 28 days with additional 14- Trial demonstrated favorable safety and tole

  23. Slide 23: Retina XR Platform

    Slide 23: Retina XR Platform

    RETINA XR PLATFORM Addressing the significant drawbacks of conventional Targeting biodegradable, small-molecule implant with therapies for retinal diseases sustained efficacy, designed to address shortcomings of conventional injections that impose tremendous treatment burdens on patients and contrib

  24. Slide 24: Retina XR: multi-kinase inhibitor durable effect in vivo

    Slide 24: Retina XR: multi-kinase inhibitor durable effect in vivo

    IVT multi-kinase inhibitor continues to demonstrate robust and durable effect in vivo Retina 40 XR: 35 Placebo Implant Vascular Leakage Score Data 30 1 MKI Implant -8.2 2 MKI Implants supports 25 -8.5 20 expedited 15 first-time-in- 10 human trial 5 in 2023 0 0 100 200 300 400 500 600 700 Days 20+ mo

  25. Slide 25: Attractive financial profile

    Slide 25: Attractive financial profile

    NET SALES SALES MIX (in millions) 6% $283 28% 20%+ 2Q Attractive 7YR CAGR 2015 49% 2023 $72 financial 94% 23% US Glaucoma profile 2015 2022 Int’l Glaucoma Corneal Health provides solid MARGINS GROSS MARGIN 1 CASH AND EQUIVALENTS2 foundation (in millions) 75% 82% 2015 $104 2014 2023 2023 $310 1 FY201

  26. Slide 26: Efficient, scalable global platform

    Slide 26: Efficient, scalable global platform

    GLOBAL COMMERCIAL COUNTRIES WITH DIRECT SALES PERSONNEL 2015 2023 2023 Complemented by 17 distributor and Efficient, hybrid models in 35 65 275+ 2014 additional countries scalable global 2 platform supports NEW STATE-OF-THE-ART HYBRID PHARMACEUTICAL MANUFACTURING FACILITY growth © 2023 Glaukos Corpo

  27. Slide 27: Our Current Portfolio

    Slide 27: Our Current Portfolio

    PRODUCT PATIENT OUR CURRENT GLAUCOMA PORTFOLIO iStent / iStent inject / iStent inject W iStent infinite Mild-to-Moderate Glaucoma with Cataract Glaucoma Standalone (failed on prior therapy) CORNEA Photrexa (Epi-off) Keratoconus MARGINS Disrupting treatment paradigms with dropless therapies that addr

  28. Slide 28: Our Future Portfolio

    Slide 28: Our Future Portfolio

    PRODUCT PATIENT OUR FUTURE GLAUCOMA PORTFOLIO iStent / iStent inject / iStent inject W iStent infinite Mild-to-Moderate Glaucoma with Cataract Glaucoma Standalone (failed on prior therapy) iStent infinite Glaucoma Standalone (label expansion) PreserFlo Advanced-Refractory Glaucoma Standalone iDose T

  29. Slide 29: Glaukos: Transforming Vision

    Slide 29: Glaukos: Transforming Vision

    GLAUKOS TRANSFORMING VISION

  30. Slide 30: Appendix: GAAP to Non-GAAP Reconciliation - 2Q 2023

    Slide 30: Appendix: GAAP to Non-GAAP Reconciliation - 2Q 2023

    Appendix GAAP to Non-GAAP Reconciliation - 2Q 2023 2Q 2023 GAAP Amort. of Dev 2Q 2023 Non-GAAP Gross Margin Tech Intangibles Gross Margin Net Sales $ 80,399 $ 80,399 COGS $ 20,103 $ (5,523) $ 14,580 Gross Profit $ 60,296 $ 5,523 $ 65,819 Gross Margin 75% 82% © 2023 Glaukos Corporation 30

  31. Slide 31: References

    Slide 31: References

    References 1 Based on company analysis of Market Scope, Medicare Claims and IMS Health Compliance data 2 Nordstrom BL, Friedman DS, Mozaffari E, Quigley H, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4): 598-606 3 Malihi M, Moura, Filho ER, Hodge DO,

Source: Internet Archive copy of s206.q4cdn.com

More decks from Glaukos Corporation

All 68 Glaukos decks